PT  - JOURNAL ARTICLE
AU  - Lederman, Lynne
ED  - Chibaudel, Benoit
TI  - Maintenance Therapy with ERL and BEV Prolongs Survival in Unresectable mCRC
DP  - 2014 Dec 01
TA  - MD Conference Express
PG  - 10--11
VI  - 14
IP  - 36
4099  - http://mdc.sagepub.com/content/14/36/10.short
4100  - http://mdc.sagepub.com/content/14/36/10.full
AB  - Cross-talk between vascular endothelial growth factor (VEGF) and the epidermal growth factor receptor (EGFR) are involved in tumor growth and survival; inhibition of either may increase survival in patients with metastatic colorectal cancer (mCRC). However, combining monoclonal antibodies (mAb) targeting VEGF or EGFR in mCRC has not been effective. This article reports on the final results of the Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery study [DREAM; NCT00265824].